[HTML][HTML] Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors
Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
[HTML][HTML] The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
YL Zhang, JQ Yuan, KF Wang, XH Fu, XR Han… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Objectives Estimate the epidermal growth factor receptor (EGFR) mutation prevalence in all
non-small cell lung cancer (NSCLC) patients and patient subgroups. Results A total of 456 …
non-small cell lung cancer (NSCLC) patients and patient subgroups. Results A total of 456 …
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung
JY Han, K Park, SW Kim, DH Lee, HY Kim… - Journal of clinical …, 2012 - ascopubs.org
Purpose Gefitinib has shown high response rate and improved progression-free survival
(PFS) in never-smokers with lung adenocarcinoma (NSLAs). We compared efficacy of …
(PFS) in never-smokers with lung adenocarcinoma (NSLAs). We compared efficacy of …
Pathology of lung cancer
WD Travis - Clinics in chest medicine, 2011 - chestmed.theclinics.com
Worldwide, lung cancer is the most common cause of major cancer incidence and mortality
in men, whereas in women it is the third most common cause of cancer incidence and the …
in men, whereas in women it is the third most common cause of cancer incidence and the …
Non–small cell lung cancer
Most patients with non–small cell lung cancer (NSCLC) are diagnosed with advanced
cancer. These guidelines only include information about stage IV NSCLC. Patients with …
cancer. These guidelines only include information about stage IV NSCLC. Patients with …
[HTML][HTML] Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS
GJ Korpanty, DM Graham, MD Vincent… - Frontiers in …, 2014 - frontiersin.org
Lung cancer remains the most lethal malignancy in the world. Despite improvements in
surgical treatment, systemic therapy, and radiotherapy, the 5-year survival rate for all …
surgical treatment, systemic therapy, and radiotherapy, the 5-year survival rate for all …
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and …
SHI Ou - Drug design, development and therapy, 2011 - Taylor & Francis
Epidermal growth factor receptor (EGFR) tyrosine inhibitors were first approved for the
treatment of non-small cell lung cancer (NSCLC) in 2003 in the US. Activating EGFR …
treatment of non-small cell lung cancer (NSCLC) in 2003 in the US. Activating EGFR …
Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence
SHI Ou - Critical reviews in oncology/hematology, 2012 - Elsevier
The discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small
cell lung cancer (NSCLC) in 2004 heralded the era of molecular targeted therapy in NSCLC …
cell lung cancer (NSCLC) in 2004 heralded the era of molecular targeted therapy in NSCLC …
Personalized medicine in lung cancer: what we need to know
TSK Mok - Nature reviews Clinical oncology, 2011 - nature.com
Lung cancer is a complex and often fatal disease. The recent discovery of activating
mutations in EGFR and fusion genes involving ALK has set the stage for personalized …
mutations in EGFR and fusion genes involving ALK has set the stage for personalized …